Ra Capital Management, L.P. Purchases 6,510,416 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. acquired 6,510,416 shares of Artiva Biotherapeutics stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $11.52 per share, with a total value of $74,999,992.32. Following the completion of the purchase, the director owned 15,203,995 shares in the company, valued at $175,150,022.40. The trade was a 74.89% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Artiva Biotherapeutics Stock Down 1.2%

Shares of Artiva Biotherapeutics stock traded down $0.13 during trading hours on Wednesday, reaching $10.50. 423,850 shares of the company’s stock were exchanged, compared to its average volume of 293,441. The business has a fifty day moving average of $7.91 and a two-hundred day moving average of $5.48. The company has a market capitalization of $259.56 million, a P/E ratio of -2.97 and a beta of 2.86. Artiva Biotherapeutics, Inc. has a 1 year low of $1.47 and a 1 year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, research analysts predict that Artiva Biotherapeutics, Inc. will post -2.88 EPS for the current year.

Artiva Biotherapeutics News Roundup

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: Needham & Company LLC sharply raised its price target on Artiva Biotherapeutics to $41.00 from $18.00 and reiterated a Buy rating, signaling significantly improved confidence in the stock’s upside. Artiva Biotherapeutics (NASDAQ:ARTV) Price Target Raised to $41.00 at Needham & Company LLC
• Positive Sentiment: HC Wainwright also maintained a Buy rating and $35.00 target, while lifting multiple earnings estimates for Q2 2026, Q3 2026, Q4 2026, and FY2026, suggesting analysts see Artiva’s near-term losses improving versus prior forecasts.
• Positive Sentiment: Additional positive analyst outlooks from Cantor Fitzgerald and Wedbush reinforced sentiment around the name, adding to the buying pressure on ARTV. Cantor Fitzgerald Issues Positive Forecast for Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price Wedbush Issues Positive Forecast for Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price
• Neutral Sentiment: HC Wainwright’s longer-term estimates were mixed: it improved some forecasts, but still projects losses through several future years, so the stock’s valuation story remains highly dependent on clinical and operating execution.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Needham & Company LLC lifted their price objective on Artiva Biotherapeutics from $18.00 to $41.00 and gave the stock a “buy” rating in a research report on Tuesday. Wedbush lifted their price target on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday. Wall Street Zen raised shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright upped their price objective on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, Cantor Fitzgerald raised their price objective on shares of Artiva Biotherapeutics from $10.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC lifted its stake in shares of Artiva Biotherapeutics by 419.3% in the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after purchasing an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after purchasing an additional 117,733 shares during the last quarter. Marshall Wace LLP purchased a new stake in Artiva Biotherapeutics in the 4th quarter valued at about $341,000. Jane Street Group LLC acquired a new position in Artiva Biotherapeutics in the second quarter valued at about $67,000. Finally, Landscape Capital Management L.L.C. purchased a new position in Artiva Biotherapeutics during the third quarter worth about $112,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.